Guideline: Pediatric Asthma Management, Inpatient Admission

This Guideline is for use in the inpatient units of Comer Children’s Hospital (Comer 3, 4, 5, 6) in the care and management of children ≥2 years old with asthma exacerbation.

Definitions:
Asthma Exacerbation: Acute episode of progressively worsening shortness of breath, cough, wheezing, and chest tightness, or some combination of these symptoms, characterized by decreases in expiratory airflow.

Status Asthmaticus: Acute asthma exacerbation unresponsive to conventional therapy with short-acting bronchodilators.

Use of Guideline:
This guideline was developed for care of children with asthma admitted into Comer Children’s Hospital and is limited to standard care of asthma exacerbation. The supervising attending physician may decide to follow or not follow this guideline. Use of this guideline outside of Comer Children’s Hospital is at the discretion of the care provider. This guideline is not intended to substitute for physician evaluation and care of a child with asthma.

Pathway Inclusion Criteria
- At least 2 years of age
- Admitted to inpatient unit for difficulty breathing +/- coughing, wheeze, or loss of respiratory sounds on auscultation
- Has either a prior diagnosis of asthma, or history taken from parent or chart is strongly suggestive of asthma (recurrent wheeze, persistent cough, or recurrent cough improved by albuterol)
- Unlikely to have the following differential diagnoses:
  + Foreign body aspiration
  + Primary cause of respiratory distress is bacterial pneumonia (based on CBC, diff, culture, exam; see Pneumonia Guidelines)
  + Anaphylaxis
  + Acute cardiac disease (pericardial effusion, pericarditis, myocarditis, etc.)
- No history of the following (exclusion criteria):
  + Cardiac lesion with potential to cause cyanosis, dyspnea, or distress
  + Other chronic respiratory disease including but not limited to cystic fibrosis, interstitial lung disease, restrictive lung disease, neuromuscular disease. If child is <5yo with strong history of chronic lung disease of prematurity/BPD, use clinical judgment.
  + Sickle cell anemia or HbgSC disease

Background and Purpose
This guideline was developed in consultation with senior and junior physicians, nurse managers, respiratory therapists, and quality improvement officers at Comer Children’s Hospital. The guideline aims to:
- Provide guidance for evidence-based management or best-practice care of asthma in hospitalized children.
- Provide objective measures for communication amongst interdisciplinary providers managing children with asthma exacerbation.
- Establish a platform for monitoring quality measures and improving care in children with asthma.
Triage and first assessment: measure PAS prior to any hospital intervention for indication of first needed intervention. For further guidance, refer to Comer Asthma ED Guidelines.

PAS before albuterol and 15-30 min after albuterol: “pre-post” assessment to check for immediate albuterol response. Decrease by 2 or more is positive response.

Pathway Uses for PAS

Scheduled PAS during continuous IV or respiratory therapy (albuterol neb, IV drip): measure every 1-2 hours to monitor child’s progress on this therapy.

Scheduled PAS measured during intermittent therapy (albuterol “q2”-“q3”-“q4”): measure at the end of the observation interval (every 2-4 hours) but prior to giving the next albuterol dose. This monitors stability on therapy or readiness to wean.

Ad hoc PAS: measure any time if patient is in distress to assess the child’s need for increased therapy.

---

**PAS: Modified and amended Pediatric Asthma Score**

PAS is used to communicate patient’s respiratory status when being treated for asthma exacerbation. Score reflects degree to which patient is supported by the respiratory intervention at that time.

<table>
<thead>
<tr>
<th>Score</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory Rate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 2-3</td>
<td>&lt;34</td>
<td>35-39</td>
<td>&gt;40</td>
</tr>
<tr>
<td>Age 4-5</td>
<td>&lt;30</td>
<td>31-35</td>
<td>&gt;36</td>
</tr>
<tr>
<td>Age 6-12</td>
<td>&lt;26</td>
<td>27-30</td>
<td>&gt;31</td>
</tr>
<tr>
<td>Age &gt;12</td>
<td>&lt;23</td>
<td>24-27</td>
<td>&gt;28</td>
</tr>
<tr>
<td><strong>O2 saturation</strong></td>
<td>&gt;95% on room air</td>
<td>90-95% room air</td>
<td>&lt;90% on room air</td>
</tr>
<tr>
<td><strong>PICU Floor</strong></td>
<td>On LFNC &lt;4L</td>
<td>On HFNC&gt;4L</td>
<td>On BiPAP</td>
</tr>
<tr>
<td><strong>Auscultation</strong></td>
<td>Normal to mild expiratory wheeze</td>
<td>Expiratory wheeze</td>
<td>Inspiratory and expiratory wheeze or diminished</td>
</tr>
<tr>
<td><strong>Retractions</strong></td>
<td>None or intercostal</td>
<td>Intercostal and substernal</td>
<td>Intercostal, substernal, supraclavicular</td>
</tr>
<tr>
<td><strong>Dyspnea</strong></td>
<td>Speaks in sentences, coos and babbles</td>
<td>Speaks in partial sentences, short cries</td>
<td>Speak in single words Grunts</td>
</tr>
</tbody>
</table>

Total Score 5-15

*Room air score preferred, if safe for patient to be checked on room air. If patient not safe to be removed from O2, adjust score as listed.
Pathway 1: Admission Pathway

This pathway provides guidance to the admitting clinician for assessment of the initial phase of asthma care.

ADMISSION FOR ASTHMA EXACERBATION ≥ 2 years old

Admitted to PICU
- Use PICU algorithm to determine initial phase
  - Critical Phase treatment
    - Discuss with PICU fellow or attending
  - Intensive Phase treatment
  - Initiate Active Phase treatment
- On continuous Albuterol upon arrival to floor?
  - YES
    - Evaluate PAS 1.5 – 2 hr from last treatment prior to arrival
      - PAS ≥ 12
        - Enter Maintenance q? Phase Treatment
      - PAS 8.11
        - Enter Maintenance q? Phase Treatment
      - PAS ≤ 7
        - Enter Maintenance q? Phase Treatment
  - NO
    - Admitted to floor

Guideline: Pediatric Asthma Management, Inpatient Admission
Admission Assessment and Orders

Exacerbation Information:
- Time of onset of symptoms/triggers
- Severity compared with past exacerbations
- Treatments offered, response

Asthma history:
- Age of diagnosis/symptom onset and classification of asthma severity
- Current outpatient medications – document prior to admission medications including doses and frequency, if known, in PTA medication tab
- Current compliance with daily medications and spacer, if prescribed MDI
- One-year history of asthma related urgent visits (PCP), ED visits, hospitalizations and number of steroid courses in last 6 months and last 12 months.
- Lifetime history of PICU admissions, BiPAP and intubations. In older children, delineate ICU stays in toddlerhood vs in grade school and above. In children with severity variations over time, specify frequency in last 1-3 years.
- Asthma control (frequency of daytime symptoms including exercise tolerance, frequency of nighttime symptoms, frequency of use of albuterol)
- Previous complications of ICS

Risks:
- Known triggers (perennial, seasonal, indoor, outdoor, viral)
- Exposure to animal dander, tobacco smoke, other smoke, pollen or trees, dust or dustmites, mold or mildew, roaches or mice, other triggers

Related history:
- History of disease-modifying respiratory and chest illness and disease e.g. obstructive sleep apnea, scoliosis, reflux
- History of atopy and family history of atopy or asthma
- Birth history, particularly prematurity or O2 requirements after birth.

Asthma-Specific Physical Exam

Vital signs including at least one SpO2 on room air (may be triage SpO2)

Neuro: Level of alertness and engagement

CV: Hydration status, perfusion, cardiac exam

Skin/MSK: Cyanosis, pallor, signs of clubbing; neck and chest wall palpation for subcutaneous emphysema

Resp: Detailed respiratory exam (rate, WOB, breath sounds, adventitial noises, symmetry vs asymmetry); current degree of airway obstruction

Administering Supportive Oxygenation:
In all phases, deliver supplemental O2 as needed to maintain FiO2 ≥ 90%

Requesting Appropriate Pulmonary Care:
It is recommended at Comer that all patients admitted for asthma are seen by a member of the Pediatric Pulmonary service during their inpatient care or by an asthma specialist in hospital follow up. A consult or referral order must be placed on each admitted patient.

Asthma Specific Investigations

For the general care of asthma exacerbation, no labs or images are necessary. Investigations may be warranted in certain circumstances; common considerations are listed.

**Chest X-ray (PA/Lateral):**
- Increased O2 requirements
- Failure to respond to treatment (48h)
- Sudden or unexplained escalation of care
- Asymmetric physical exam
- Admission (to PICU) on positive pressure ventilation
- Subcutaneous emphysema

**RVP**
Useful in cases of suspected influenza (high fever and myalgia during circulating season)

**Laboratory investigations**
- High grade fever, chills, or clinical signs of SIRS, pneumonia, or sepsis
- Other systemic illness, acute or chronic, raising concern for intervention
- Difficulty in clinically assessing oxygenation and ventilation (consider arterial blood gas measurements)
**Pathway 2: Phases of Inpatient Asthma Care**

**Critical (PICU)**
- Refer to PICU guidelines for tier 3 management and dosing
- Continuous albuterol 0.5mg/kg/hr (max 20mg/hr)
- +/- Scheduled Atrovent or Mag, ketamine, terbutaline, aminophylline; prn IM epinephrine
- Hourly PAS score (even hours: RN, odd hours: RT)
- Primary dx: Near-Fatal Asthma

**Intensive (PICU)**
- Continuous albuterol neb, 5-15mg/hr
- Solumedrol 0.5mg/kg IV q6 or 1mg/kg q12
- +/- HFNC
- +/- Atrovent or Mag
- Floor: Q2 PAS (RT only)
- PICU: Q1 PAS (RN/RT alternating)
- IV fluids (w/D5) and NPO
- Notify PCP of admission
- Primary dx: Status asthmaticus

**Active**
- Continuous albuterol neb, 5-15mg/hr
- Solumedrol 0.5mg/kg IV q6 or 1mg/kg q12
- +/- HFNC
- +/- Atrovent or Mag
- Floor: Q2 PAS (RT only)
- PICU: Q1 PAS (RN/RT alternating)
- IV fluids (w/D5) and NPO
- Notify PCP of admission
- Primary dx: Status asthmaticus

**Maintenance/“Q2”**
- Albuterol q2h MDI
- Prednisolone 2mg/kg qd, max 60mg
- D/C scheduled atrovent/mag
- +/- O2
- PO diet, off IVF
- D/c atrovent, mag
- Q2 PAS (RT)
- Initiate asthma education (MDs)
- Book f/u appts
- Primary dx: Asthma exacerbation

**Resolution**
- Albuterol q4h MDI
- Prednisolone
- Off O2
- Q4 PAS (RT)
- Ensure completion of home Rx, all education, appts, AAP
- Notify PCP if >48hr stay
- Prep for d/c (stable on q4h x1)
- Refer to discharge list
- Primary dx: Asthma exacerbation

*Guideline: Pediatric Asthma Management, Inpatient Admission*
Critical (PICU)
Phase for most critically ill patients. Medication dosing and frequency should be performed in consultation with PICU attending and fellow. Frequent reassessment by all team members is necessary.

- Appropriate for PICU only, consult PICU Asthma guidelines for “tier 3” management and medication dosing.
- Continuous albuterol nebulization 0.5mg/kg/hr (max 20mg/hr)
- Solumedrol 1mg/kg IV q6
- Interventions may include scheduled Atrovent, Scheduled Magnesium, prn IM epinephrine, infusion of terbutaline, aminophylline or ketamine
- Maintenance IV fluids; may include potassium chloride, consider 20-40 meq/L
- Hourly PAS is logged on Asthma Score Flowsheet. Even hours performed and logged by RN; odd hours performed and logged by RT.
- Primary diagnosis if this stage is reached is Near-Fatal Asthma

Intensive (PICU)
Phase for patients requiring positive pressurized airflow or helium. Frequent reassessment by all team members is recommended.

- Appropriate for PICU only; consult additional PICU Asthma guidelines for “tier 1” and “tier 2” management and medication dosing.
- BiPAP ≤ 14/7 or TV 6-9ml/kg and/or Heliox 60/40 or 70/30
- Continuous albuterol nebulization between 5-20mg/hr
- Solumedrol 1mg/kg IV q6
- Interventions may include scheduled Atrovent or Magnesium; prn IM Epi
- Maintenance IV fluids; may include potassium chloride, consider 20-40 meq/L
- Hourly PAS is logged on Asthma Score Flowsheet. Even hours performed and logged by RN; odd hours performed and logged by RT.
- Primary diagnosis is Status Asthmaticus

Active
Phase for patients requiring continuous albuterol administration through face mask or nasal cannula. Active monitoring by resident team and reassessment throughout the day by all team members is recommended.

- Continuous albuterol neb may be given from 5 - 15mg/hour.
- Solumedrol 0.5mg/kg IV q6h or 1mg/kg q12h. A maximum dose of 60-80mg is generally considered appropriate.
- Intervention may involve heated and humidified O2 4L-6L. This is not available on Comer 6. It is available up to 6L on Comer 5.
- Intervention may involve Atrovent 500mcg every 2 hours by nebulizer.
- Intervention may include Magnesium sulfate 50mg/kg IV. Maximum dose is 2g, and minimum interval between doses is 6 hours. On Comer 5 and 6, this is limited to as needed dosing. In PICU, dosing may be scheduled q6 or as needed.
- On Comer 5/6, PAS is logged on Asthma Score Flowsheet every 2 hours by RT. In PICU, PAS is logged on even hours by RN; odd hours are logged by RT.
- Dextrose-containing IV fluids at maintenance or greater
- NPO (no food or drink by mouth); g-tube feeds at discretion of attending
- Notification to Primary Care Provider of admission may be done by MD or resident extender.
- Primary diagnosis is Status Asthmaticus
Phases of Asthma Management Checklist

### Maintenance / “Q2”

Phase for patients requiring albuterol every two hours. Reassessment throughout the day by all several team members is recommended. Patient education and follow up plans are integrated into care.

- Albuterol q2h by metered dose inhaler and spacer only.
- Prednisone or Prednisolone 2mg/kg qd, max 60mg. If converting from a q12 or q6 IV dose, start next dose at 9am the next day. If continuing from first dose of 2mg/kg, give dose 24 hours after first dose.
- Interventions may include supplemental O2 ≤ 4L. If available, patient may maintain heated humidified flow ≤4L.
- Allow PO diet or g-tube feeds. If weaning from continuous albuterol, nursing to monitor for stability for 1-2 hours prior to eating.
- Discontinue maintenance IV fluids if patient able to maintain adequate fluid intake by PO/GT. May saline lock IV to allow mobility.
- Discontinue any Atrovent nebs and scheduled magnesium orders.
- PAS logged every 2 hours by RT on Asthma Score Flowsheet.
- Initiate asthma education. Residents, nursing, and RT may participate in team-based asthma education as appropriate.
- Prepare for discharge and home care, including notifying parent of possible discharge in 12-24 hours.
- Prepare for outpatient follow up with PCP in one week.
- Prepare for outpatient follow up with an asthma specialist such as Pediatric Pulmonology, Allergist, or other dedicated asthma clinic in 4-8 weeks.
- Primary diagnosis is Status Asthmaticus

### Maintenance / “Q3”

Phase for patients requiring albuterol every three hours. Reassessment throughout the day by select team members is recommended. Recommend preparing for discharge.

- Albuterol q3h by metered dose inhaler and spacer only
- Prednisone or Prednisolone 2mg/kg qd, max 60mg. If continuing from first dose of 2mg/kg, give dose 24 hours after first dose.
- Interventions may include supplemental O2 ≤ 4L. Patient should be weaned off O2 during phase.
- If off O2, discontinue daytime continuous monitoring using order “Limited Pediatric Continuous Pulse Oximetry.”
- Start controller medication for eligible patients. Patients who will receive a change in controller management can be started on new controller. Patients with no change can be started on pre-admission controller. If home medication is not available on formulary, use equivalent on-formulary medication or patient’s home medication.
- PAS logged every 3 hours by RT on Asthma Score Flowsheet.
- Teaching of proper inhaler technique conducted by RT. All metered dose inhalers (controllers and rescue) must be taught with a spacer. Mask need is determined by patient age and coordination.
- Discharge preparations include notifying parent of probable discharge in 6-12 hours (if reaching phase after 2pm, assume discharge no sooner than the following morning).
- Complete all follow up and education as listed in Maintenance Q2 Phase. Prepare, print, and review the Asthma Action Plan with the family. Prepare all prescriptions and advise parent on obtaining medications outpatient.
- If this is the most severe phase reached by patient in this admission, the primary diagnosis is asthma exacerbation.
Resolution

Phase for patients requiring albuterol every four hours. Patient’s exacerbation has resolved at this stage and discharge may be anticipated.

- Albuterol q4h by metered dose inhaler and spacer. Patient may be monitored 4 hours between albuterol doses at least once, without need for intervention, i.e. “Q4 x 1.”
- Prednisone or Prednisolone 2mg/kg qd, max 60mg. If continuing from first dose of 2mg/kg, give dose 24 hours after first dose. Total course of steroids is at least 5 days. For steroid courses ≥ 8 days due to duration of airflow obstruction, consider a taper.
- Off all oxygen and supportive flow.
- PAS logged every four hours by RT on Asthma Score Flowsheet.
- Ensure patient has received education, appointments, Asthma Action Plan, and prescriptions as listed in the Maintenance phases.
- Discuss continuing management of this exacerbation with parent (i.e. albuterol frequency of Q4 today and home steroid course).
- If inpatient stay was >48 hours, notify the PCP of discharge.
- Notify attending and bedside nurse of plan to discharge.
- If this is the most severe phase reached by patient, the primary diagnosis is asthma exacerbation.

Discharge criteria

- **Respiratory Rate**: Patient meets “1 point” criteria of PAS scoring
- **Retractions and Dyspnea**: Patient meets “1 point” criteria of PAS scoring
- **Auscultation**: Patient meets “1 point” criteria of PAS scoring, and/or has mild crackles
- **SpO2**: ≥ 94% on spot check, off all O2 for minimum of 4 hours
- **Albuterol**: Successfully observed off albuterol for at least 4 hours i.e. “Q4 x 1.”
- **Education**: Complete Asthma Action Plan printed and reviewed with patient/family
- **Family Centrality**: Parent/teen comfortable with home management
- **Continuity**: Follow up appointments scheduled by team or patient’s family including primary care physician in 1 week and asthma specialist within 4-8 weeks.
Pathway 3: Algorithms for Weaning, Maintaining, or Escalating Care

Comer 5 and 6

Established in current phase. Assess PAS q1-4 hr per phase.

- PAS 12-15
- PAS 8-11
- PAS ≤ 7

On current therapy for more than 12 hrs?

- Yes
  - Stable in between treatments?
    - Yes
      - WEAN Decrease therapy
    - No
      - PAS decrease (improve) by ≥ 2 points?
        - Yes
          - STAY Keep therapy
        - No
          - Re-assess in 30 min

- No
  - Received albuterol within 30 min or just started continuous?
    - Yes
      - Can phase be escalated on floor?
        - Yes
          - Stat albuterol and increase phase now
        - No
          - Increase therapy within phase now
    - No
      - Can care increase in current phase?
        - Yes
          - Is PAS ≥ 12?
            - Yes
              - Reseas 60 min x1
            - No
              - Resume phase of care management
        - No
          - Can patient be safely monitored on floor?
            - Yes
              - Discuss with team, monitor up to 90 min
            - No
              - Call PET

Comer PICU

Assess PAS q1 hour per phase.

- PAS > 7
  - ESCALATE Increase therapy
- PAS ≤ 7
  - PAS worsened by ≥ 2
    - Yes
      - WEAN Decrease therapy
    - No
      - PAS improved by ≥ 2
        - Yes
          - WEAN Decrease therapy
        - No
          - STAY Keep therapy
Cross Reference to the Following Hospital Policies: Comer ER Asthma Pathway, Comer PICU Asthma Pathway, PET Policy, and Pneumonia Guidelines

Corresponding order sets:
- Comer 5/6: IP Pediatric Asthma Admission order set (718) (revisions pending)
- PICU: IP Pediatric PICU Asthma Admission order set (3484) (updated Fall 2015)

Created by: Ajanta Patel MD MPH, Molly Phillips DO, and B. Louise Giles MD, in consultation with Pediatric Intensive Care Unit Faculty (Jason Kane MD, Cathy Humikowski MD), Pediatric Hospital Medicine Faculty (H. Barrett Fromme MD), Respiratory Therapy Leadership (Kathy Myktiuk RT), Nursing Leadership (Monica Gonzalez APN CCRN, Tamia Walker RN, et al.), Chief Residents and Resident Representatives (Jarrett Linder MD, Megan Spokes MD, Matt Howard MD, Sid Dante MD, John Palla MD et al), Center for Quality Project Managers (Samira Qadir, Natalie Mikat-Stevens), and numerous other staff at Comer Children’s Hospital.

Date: April 25, 2016

Reviewed by: Comer Hospital Quality Review Committee and Section of Pediatric Pulmonology

Approved on (date): April 15, 2016

References:


